eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
5/2016
vol. 8
 
Share:
Share:
more
 
 
abstract:
Original paper

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

Naoya Murakami, Kazuma Kobayashi, Tomoyasu Kato, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Satoshi Shima, Keisuke Tsuchida, Tairo Kashihara, Ken Harada, Kana Takahashi, Rei Umezawa, Koji Inaba, Yoshinori Ito, Hiroshi Igaki, Jun Itami

J Contemp Brachytherapy 2016; 8, 5: 391–398
Online publish date: 2016/10/10
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Purpose: The aim of this study was to report the clinical results of uterine cervical cancer patients treated by primary radiation therapy including brachytherapy, and investigate the role of interstitial brachytherapy (ISBT).

Material and methods: All consecutive uterine cervical cancer patients who were treated by primary radiation therapy were reviewed, and those who were treated by ISBT were further investigated for clinical outcomes and related toxicities.

Results: From December 2008 to October 2014, 209 consecutive uterine cervical cancer patients were treated with primary radiation therapy. Among them, 142 and 42 patients were treated by intracavitary and hybrid brachytherapy, respectively. Twenty-five patients (12%) were treated by high-dose-rate (HDR)-ISBT. Five patients with distant metastasis other than para-aortic lymph node were excluded, and 20 patients consisted of the analysis. Three-year overall survival (OS), progression-free survival (PFS), and local control (LC) rate were 44.4%, 38.9%, and 87.8%, respectively. Distant metastasis was the most frequent site of first relapse after HDR-ISBT. One and four patients experienced grade 3 and 2 rectal bleeding, one grade 2 cystitis, and two grade 2 vaginal ulcer.

Conclusions: Feasibility and favorable local control of interstitial brachytherapy for locally advanced cervical cancer was demonstrated through a single institutional experience with a small number of patients.
keywords:

cervical cancer, primary radiotherapy, interstitial brachytherapy

references:
Viswanathan AN, Thomadsen B. American Brachytherapy Society Cervical Cancer Recommendations Committee; American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 2012; 11: 33-46.
Viswanathan AN, Beriwal S, De Los Santos JF et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 2012; 11: 47-52.
Bethesda M. ICRU report 38. Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU 1985; 38: 1-20.
Tod M, Meredith WJ. Treatment of cancer of the cervix uteri, a revised Manchester method. Br J Radiol 1953; 26: 252-257.
Haie-Meder C, Pötter R, Van Limbergen E et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005; 74: 235-245.
Pötter R, Haie-Meder C, Van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D imagebased treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006; 78: 67-77.
Dimopoulos JC, Lang S, Kirisits C et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75: 56-63.
Nag S, Cardenes H, Chang S et al. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. Int J Radiat Oncol Biol Phys 2004; 60: 1160-1172.
Dimopoulos JC, Kirisits C, Petric P et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: clinical feasibility and preliminary results. Int J Radiat Oncol Biol Phys 2006; 66: 83-90.
Jürgenliemk-Schulz IM, Tersteeg RJ, Roesink JM et al. MRI- guided treatment-planning optimization in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiother Oncol 2009; 93: 322-330.
Tan PW, Koh VY, Tang JI. Outpatient combined intracavitary and interstitial cervical brachytherapy: barriers and solutions to implementation of a successful programme – a single institutional experience. J Contemp Brachytherapy 2015; 7: 259-263.
Bailleux C, Falk AT, Chand-Fouche ME et al. Concomitant cervical and transperineal parametrial high-dose-rate brachytherapy boost for locally advanced cervical cancer. J Contemp Brachytherapy 2016; 8: 23-31.
Kuroda Y, Murakami N, Morota M et al. Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer. J Radiat Res 2012; 53: 588-593.
Toita T, Ohno T, Kaneyasu Y et al. A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol 2010: 40: 456-463.
Ebina Y, Yaegashi N, Katabuchi H et al. Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. Int J Clin Oncol 2015; 20: 240-248.
Murakami N, Kasamatsu T, Wakita A et al. CT based three- dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer. BMC Cancer 2014; 14: 447-454.
Yoshio K, Murakami N, Morota M et al. Inverse planning for combination of intracavitary and interstitial brachytherapy for locally advanced cervical cancer. J Radiat Res 2013; 54: 1146-1152.
Itami J, Hara R, Kozuka T et al. Transperineal high-dose-rate interstitial brachytherapy in the management of gynecologic malignancies. Strahlenther Onkol 2003; 179: 737-741.
Murakami N, Kasamatsu T, Sumi M et al. Vaginal tolerance of CT based image-guided high-dose rate interstitial brachytherapy for gynecological malignancies. Radiat Oncol 2014; 9: 31-38.
Murakami N, Kato T, Miyamoto Y et al. Salvage high-dose-rate interstitial brachytherapy for pelvic recurrent cervical carcinoma after hysterectomy. Anticancer Res 2016; 36: 2413-2421.
Rao PB, Ghosh S. Routine use of ultrasound guided tandem placement in intracavitary brachytherapy for the treatment of cervical cancer – a South Indian institutional experience. J Contemp Brachytherapy 2015; 7: 352-356.
Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-528.
Bentzen SM, Dörr W, Gahbauer R et al. Bioeffect modeling and equieffective dose concepts in radiation oncology – terminology, quantities and units. Radiother Oncol 2012; 105: 266-268.
Fowler JF. Sensitivity analysis of parameters in linear-quadratic radiobiologic modeling. Int J Radiat Oncol Biol Phys 2009; 73: 1532-1537.
Martinez A, Cox RS, Edmundson GK. A multiple-site perineal applicator (MUPIT) for treatment of prostate, anorectal, and gynecologic malignancies. Int J Radiat Oncol Biol Phys 1984; 10: 297-305.
Syed AM, Puthawala AA, Abdelaziz NN et al. Long-term results of low-dose-rate interstitial-intracavitary brachytherapy in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2002; 54: 67-78.
Nag S, Martinez-Monge R, Selman AE et al. Interstitial bra­chytherapy in the management of primary carcinoma of the cervix and vagina. Gynecol Oncol 1998; 70: 27-32.
Demanes DJ, Rodriguez RR, Bendre DD et al. High dose rate transperineal interstitial brachytherapy for cervical cancer: high pelvic control and low complication rated. Int J Radiat Oncol Biol Phys 1999; 45: 105-112.
Yoshida K, Yamazaki H, Takenaka T et al. A dose-volume analysis of magnetic reasonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer. Int J Radiat Oncol Biol Phys 2010; 77: 765-772.
Yoshida K, Yamazaki H, Takenaka T et al. Preliminary results of MRI-assisted high-dose-rate interstitial brachytherapy for uterine cervical cancer. Brachytherapy 2015; 14: 1-8.
Lee JI, Viswanathan AN. Predictors of toxicity after image- guided high-dose-rate interstitial brachytherapy for gynecologic cancer. Int J Radiat Oncol Biol Phys 2012; 84: 1192-1197.
Sturdza A, Pötter R, Fokdal LU et al. Image guided bra­chytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radiother Oncol 2016; 120: 428-433.
Mileshkin L, Narayan K, King M et al. A phase III trial of adjuvant chemotherapy as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK Trial (ANZGOG 0902/GOG-0274/RTOG 1174).
Tamaki T, Ohno T, Noda S et al. Filling the gap in central shielding: three-dimensional analysis of the EQD2 dose in radiotherapy for cervical cancer with the central shielding technique. J Radiat Res 2015; 56: 804-810.
Toita T, Kitagawa R, Hamano T et al. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol 2012; 126: 211-216.
Toita T, Kato S, Niibe Y et al. Prospective multi-institutional study of definitive radiotherapy with high-dose-rate intracavitary brachytherapy in patients with nonbulky (<4-cm) stage I and II uterine cervical cancer (JAROG0401/JROSG04-2). Int J Radiat Oncol Biol Phys 2012; 82: e49-56.
Yoshida K, Yamazaki H, Kotsuma T et al. Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size? Brachytherapy 2016; 15: 57-64.
 
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe